Contents
Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. CMC Markets: An Overview After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. For example, a price above its moving average is generally considered an upward trend or a buy.
The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades. Shares Sold ShortThe total number of shares of a security that have been sold short and not yet repurchased.Change from LastPercentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month.Percent of FloatTotal short positions relative to the number of shares available to trade. Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market.
Verify your identity, personalize the content you receive, or create and administer your account. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have Ayondo Forex Broker Review unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. Information is provided ‘as-is’ and solely for informational purposes and is not advice.
Upgrade your FINVIZ experience
The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov, and Robert S. Langer, Jr. Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which…
- High institutional ownership can be a signal of strong market trust in this company.
- ISPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.
- The individuals or entities selected as “gurus” may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein.
- 5 Stocks Under $10 to Trade for Big BreakoutsThese stocks trading for less than $10 a share are within range of triggering breakout trades and moving much higher from current levels.
- An affiliate of Public may be “testing the waters” and considering making an offering of securities under Tier 2 of Regulation A. No money or other consideration is being solicited and, if sent in response, will not be accepted.
No offer to buy securities can be accepted, and no part of the purchase price can be received, until an offering statement filed with the SEC has been qualified by the SEC. An indication of interest to purchase securities involves no obligation or commitment of any kind. Free trading of stocks, ETFs, and options refers to $0 commissions for Webull Financial LLC self-directed individual cash or margin brokerage accounts and IRAs that trade U.S. listed securities via mobile devices, desktop or website products. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
Account
Pulmatrix, Inc. is a clinical stage biotechnology company engaged in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. The firm focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov, and Robert S. Langer, Jr. on June 15, 2015 and is headquartered in Lexington, MA.
News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services. All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.
The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition, the Company focuses on pulmonary diseases through collaboration with partners, including PUR0200, a generic in clinical development for chronic obstructive pulmonary disease. Looking for continuation and possible breakout today in PULM Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs.
Top institutional investors include Renaissance Technologies LLC (3.31%) and Vanguard Group Inc. (1.30%). 8 people have added Pulmatrix to their MarketBeat watchlist in the last 30 days. 1 people have searched for PULM on MarketBeat in the last 30 days. Pulmatrix does not have a long track record of dividend growth. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.
Pulmatrix
Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE , which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways. Market Cap is calculated by multiplying the number of shares outstanding by the stock’s price. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded.Dividend YieldA company’s dividend expressed as a percentage of its current stock price. 1 brokers have issued twelve-month target prices for Pulmatrix’s shares.
Provide specific products and services to you, such as portfolio management or data aggregation. WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns. What analysts recommend for PULM stock, on a scale from 1 to 5. Securities trading is offered to self-directed customers by Webull Financial LLC, a broker dealer registered with the Securities and Exchange Commission .
The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure. We sell different types of products MTrading and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management.
Why Splunk Is Trading Lower By Around 10%; Here Are 28 Stocks Moving Premarket
Pulmatrix’s stock reverse split on the morning of Tuesday, March 1st 2022. The 1-20 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Pulmatrix’s stock was trading at $8.76 at the start of the year.
PULM fair value
Since then, PULM shares have decreased by 56.4% and is now trading at $3.82. The company’s average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings. Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes.
Real-time analyst ratings, insider transactions, earnings data, and more. You can find your newly purchased Pulmatrix stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, and alternative assets. Discuss news and analysts’ price predictions with the investor community. No content on the Webull Financial LLC website shall be considered as a recommendation or solicitation for the purchase or sale of securities, options, or other investment products.